Core Viewpoint - Adma Biologics has shown strong stock performance recently, significantly outperforming the broader market and its industry, raising questions about its future trajectory [2][16]. Earnings Estimate Revisions - For the current quarter, Adma Biologics is expected to report earnings of $0.16 per share, reflecting a 100% increase year-over-year, with a 6.7% upward revision in estimates over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year is $0.71, indicating a 44.9% year-over-year increase, with a 3.7% upward revision in the last month [5]. - For the next fiscal year, the consensus estimate is $0.93, representing a 31% increase from the previous year, with a 6.9% upward revision [6]. - The Zacks Rank for Adma Biologics is 2 (Buy), indicating a positive outlook based on recent earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $119.1 million, showing a year-over-year increase of 45.5% [9]. - For the current fiscal year, the sales estimate is $495.8 million, indicating a 16.3% increase, while the next fiscal year's estimate is $611.5 million, reflecting a 23.3% increase [9]. Last Reported Results and Surprise History - In the last reported quarter, Adma Biologics achieved revenues of $117.55 million, a 59.1% year-over-year increase, and an EPS of $0.14 compared to $0.04 a year ago [11]. - The company exceeded consensus revenue estimates in all four of the last quarters and surpassed EPS estimates three times [11]. Valuation - Adma Biologics has a Zacks Value Style Score of D, indicating it is trading at a premium compared to its peers [15].

Core Viewpoint - Adma Biologics (ADMA) shares have increased by 22.2% in the past four weeks, closing at $19.65, with a potential upside of 39.1% based on Wall Street analysts' mean price target of $27.33 [1] Price Targets - The average price target consists of three estimates ranging from a low of $25 to a high of $32, with a standard deviation of $4.04, indicating a potential increase of 27.2% to 62.9% from the current price [2] - A low standard deviation suggests a strong agreement among analysts regarding the price movement of ADMA shares, which can serve as a starting point for further research [7] Analyst Sentiment - Analysts have shown increasing optimism about ADMA's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [9] - Over the last 30 days, two earnings estimates for ADMA have been revised upward, leading to a 3.7% increase in the Zacks Consensus Estimate [10] Zacks Rank - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [11] Conclusion on Price Targets - While consensus price targets may not be entirely reliable for predicting stock gains, they can provide a useful guide for understanding potential price movements [12]

Company Overview - Adma Biologics (ADMA) shares increased by 10.2% to close at $20.61, with a notable trading volume compared to normal sessions, and a total gain of 15.7% over the past four weeks [1][2] Revenue Growth - In 2024, Adma Biologics reported total revenues of $426.5 million from product sales, marking a 65% year-over-year increase [2] Earnings Expectations - The company is projected to report quarterly earnings of $0.16 per share, reflecting a 100% year-over-year change, with expected revenues of $119.1 million, up 45.5% from the same quarter last year [3] Earnings Estimate Revisions - The consensus EPS estimate for the upcoming quarter has been revised 6.7% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Industry Context - Adma Biologics operates within the Zacks Medical - Biomedical and Genetics industry, where Wave Life Sciences (WVE) has seen a 2.6% increase in its stock price, but has returned -11.2% over the past month [4]

Group 1 - Adma Biologics closed at $18.67, with a +1.3% increase, outperforming the S&P 500's gain of 0.64% [1] - The stock has gained 15.91% over the past month, contrasting with the Medical sector's loss of 0.88% and the S&P 500's loss of 7.69% [1] Group 2 - The upcoming earnings release is expected to show an EPS of $0.16, representing a 100% increase from the prior-year quarter, with quarterly revenue projected at $119.1 million, up 45.46% year-over-year [2] - For the full year, analysts expect earnings of $0.70 per share and revenue of $495.8 million, indicating changes of +42.86% and +16.26% respectively from last year [3] Group 3 - Recent modifications to analyst estimates for Adma Biologics reflect short-term business trends, with positive revisions indicating a favorable business outlook [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks Adma Biologics as 2 (Buy), with a 1.46% rise in the Zacks Consensus EPS estimate over the past month [5][6] Group 4 - Adma Biologics has a Forward P/E ratio of 26.52, which is a premium compared to the industry's average Forward P/E of 19.99 [7] - The Medical - Biomedical and Genetics industry holds a Zacks Industry Rank of 73, placing it in the top 30% of over 250 industries [7][8]

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Adma Biologics (ADMA), and emphasizes the importance of using these recommendations in conjunction with other analytical tools for making investment decisions [1][4]. Group 1: Brokerage Recommendations - Adma Biologics has an average brokerage recommendation (ABR) of 1.00, indicating a Strong Buy, based on recommendations from three brokerage firms, all of which are Strong Buy [2]. - The article highlights that brokerage recommendations may not be reliable indicators of stock performance, as studies show they often fail to guide investors effectively [4][5]. - Analysts from brokerage firms tend to exhibit a positive bias in their ratings due to vested interests, leading to a disproportionate number of favorable recommendations compared to negative ones [5][9]. Group 2: Zacks Rank vs. ABR - The Zacks Rank is presented as a more reliable tool for predicting stock price movements, based on earnings estimate revisions, and is classified into five groups from Strong Buy to Strong Sell [7][10]. - Unlike the ABR, which may not be up-to-date, the Zacks Rank reflects timely changes in earnings estimates, making it a more effective indicator for near-term stock performance [11]. - Adma Biologics currently holds a Zacks Rank 2 (Buy), supported by a 1.5% increase in the Zacks Consensus Estimate for the current year, indicating positive sentiment among analysts regarding the company's earnings prospects [12][13].

Core Viewpoint - ADMA Biologics (ADMA) shows potential for significant upside, with a mean price target of $26 indicating a 52.9% increase from the current price of $17.01 [1] Price Targets - The average price target consists of three estimates ranging from $25 to $28, with a standard deviation of $1.73, suggesting a consensus among analysts [2] - The lowest estimate indicates a 47% increase, while the highest suggests a 64.6% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [7] Analyst Sentiment - Analysts have shown increasing optimism about ADMA's earnings prospects, as evidenced by upward revisions in EPS estimates [9] - The Zacks Consensus Estimate for the current year has increased by 1.5% due to one upward revision and no negative revisions in the last 30 days [10] - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as they can often mislead investors [3][5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]